Genome-wide loci for fasting glucose (FG), fasting insulin (FI), FI (adjusted for BMI) and 2hGlu are shown along with results for the other traits aligned to the trait-raising allele for the primary trait. Non-MAGIC SNPs (identified in other consortia and selected for the Metabochip to follow up on other non-MAGIC traits) are indicated in bold. Freq., allele frequency of the primary trait-raising allele. Per-allele effect (standard error, SE) for FI represents differences in natural log-transformed levels of FI. N represents sample size. Heterogeneity was assessed using the I 2 index 56 . The gene shown is the nearest gene to the lead SNP, except for those marked with an asterisk, for which the nearest gene is also listed in supplementary table 2a-d.
Through genome-wide association meta-analyses of up to 133,010 individuals of European ancestry without diabetes, including individuals newly genotyped using the Metabochip, we have increased the number of confirmed loci influencing glycemic traits to 53, of which 33 also increase type 2 diabetes risk (q < 0.05). Loci influencing fasting insulin concentration showed association with lipid levels and fat distribution, suggesting impact on insulin resistance. Gene-based analyses identified further biologically plausible loci, suggesting that additional loci beyond those reaching genome-wide significance are likely to represent real associations. This conclusion is supported by an excess of directionally consistent and nominally significant signals between discovery and follow-up studies. Functional analysis of these newly discovered loci will further improve our understanding of glycemic control. glycemic traits. This approach identified 41 glycemic associations not previously described 1,2 : 20 for fasting glucose concentration, 17 for fasting insulin concentration and 4 for 2hGlu. This raises the number of associated loci to 36 for fasting glucose concentration, 19 for fast ing insulin concentration and 9 for 2hGlu, explaining 4.8%, 1.2% and 1.7% of the variance in these traits, respectively. Of these 53 non overlapping loci, 33 were also associated with T2D (P < 0.05), which, although supporting the previous assertion of an imperfect correla tion between these traits, also implicates new loci in the etiology of T2D and increases the overlap between glycemic and T2D loci.
RESULTS

Approaches to identify loci associated with glycemic traits
To follow up loci showing evidence of association (P discovery < 0.02) in discovery GWAS, we investigated the 66,000 Metabochip follow up SNPs for association with fasting glucose concentration, fasting insulin concentration and 2hGlu. We combined in metaanalysis data from up to 133,010 (fasting glucose), 108,557 (fasting insulin) and 42,854 (2hGlu) nondiabetic individuals of European ancestry, including individuals from the previous metaanalyses 1,2 , individuals from new GWAS and individuals newly genotyped on the Metabochip array ( Supplementary Fig. 2 ). All study characteristics are shown in Supplementary Table 1 . Genomewide association data for Filipino women were available ( Supplementary Table 1 ), for which we report the effect directions and allele frequencies (Supplementary Table 2a,b) . Association signals at genomewide significance (P < 5 × 10 −8 ) located more than 500 kb from and not in linkage disequilibrium (LD; HapMap Utah residents of Northern and Western European ancestry (CEU) r 2 < 0.05) with any variant already known to be associated with the trait were considered novel. Associated loci are referred to by the name of the nearest gene, unless a more biologically plausible gene was nearby or a nearby gene was previously associated with another Largescale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways The MetaAnalyses of Glucose and Insulinrelated traits Consortium (MAGIC) previously undertook metaanalyses of genomewide asso ciation studies (GWAS) of glycemic traits in nondiabetic individuals, leading to the discovery of multiple associated loci: 16 for fasting glu cose concentration, 2 for fasting insulin concentration and 5 for post challenge glucose concentration (2hour glucose, 2hGlu) [1] [2] [3] . These and subsequent studies highlighted important biological pathways implicated in glucose and insulin regulation 4, 5 . They also showed that some but not all loci associated with glycemic traits in nondiabetic individuals also affect the risk of type 2 diabetes (T2D) 1, 6 . Despite the success of these efforts, the identification of new loci was limited by de novo genotyping capacity and cost, such that only a limited number of promising loci from discovery analyses were taken forward to follow up analyses (often those reaching a threshold of approximately P < 1 × 10 −5 in the discovery phase). Therefore, it is likely that many additional associations with common, lowpenetrance variants remain to be found among SNPs not previously selected for followup 7, 8 .
The Illumina CardioMetabochip (Metabochip) is a custom iSE LECT array of 196,725 SNPs developed to support costeffective largescale followup studies of putative association signals for a range of cardiovascular and metabolic traits (~66,000 SNPs) and to fine map established loci (~120,000 SNPs) ( Supplementary Fig. 1) 9 . The ~66,000 SNPs for followup analysis were selected to enable geno typing of the most significant association signals for each of 23 meta bolic traits for which data were contributed by a range of consortia. MAGIC contributed ~5,000 topranking SNPs for fasting glucose concentration and ~1,000 SNPs each for fasting insulin concentration and 2hGlu that had shown nominal association in discovery analyses (P discovery < 0.02) 1, 2 .
In the present study, we combined newly available samples with genotype data for these 66,000 followup SNPs with previous discovery metaanalyses to discover new association signals with A r t i c l e s glycemic trait. In such cases, we maintain consistency with the pre vious naming or name the most biologically plausible gene (nearest genes are named in Supplementary Table 2a-d) . As body mass index (BMI) is a major risk factor for T2D and is correlated with glycemic traits, we also performed analyses adjusted for BMI.
Although not the main focus of this effort, given the increased variant density available on the Metabochip for established glycemic loci, we investigated whether these data would enable fine mapping of underlying functional variants [1] [2] [3] . In these analyses, we included data from up to 53,622 individuals for fasting glucose, 42,384 for fasting insulin and 27,602 for 2hGlu from studies with Metabochip geno types only. However, given the lack of samples from different ancestry groups and the absence of full conditional analyses, these analyses for the most part did not improve the resolution of association signals.
Beyond singleSNP investigations for each glycemic trait, we also tested the hypothesis that genebased analyses using VEGAS 10 would identify genes that harbor multiple association signals, which individually did not reach genomewide significance. Among the ~66,000 SNPs, we used VEGAS to pool the results for all SNPs within 50 kb of either side of gene boundaries to identify genes with more evidence of association than expected by chance (given gene size and LD structure) by simulation that was significant after Bonferroni correction for multiple testing (P < 5 × 10 −6 ).
Fasting glucose concentration
In analyses of up to 133,010 individuals, we identified 20 loci with genomewide significant associations with fasting glucose (P < 5 × 10 −8 ) ( Table 1 and Supplementary Figs. 3 and 4 ) and confirmed previously established loci 1 ( Supplementary Table 2e ). Of these 20 loci, 9 (in or near IBKAP, DNLZ, WARS, KL, TOP1, P2RX2, AMT, RREB1 and GLS2) had not previously been associated with other metabolic traits (Box 1). Among these, KL (encoding klotho) is of particular interest. In addition to being associated with fasting glucose (but not fasting insulin) concentration, the glucoseraising allele is also associated with an increased risk of T2D (odds ratio (OR) = 1.08 (1.04-1.11); P = 1.1 × 10 −5 ) ( Fig. 1) . KL was first identified as a gene related to suppression of aging: its reduced expression was associated with reduced lifespan, as well as hypoglycemia 11 . Despite further animal studies supporting a role for KL in glucose metabolism 12 and insulin sensitivity 13 , human studies have generally been small and inconclusive 14, 15 .
We also identified new associations with fasting glucose concen tration in regions previously associated with other metabolic traits or disease outcomes, including T2D 6, 16 (ARAP1, CDKN2B, GRB10, CDKAL1, IGF2BP2 and ZBED3, which was identified in BMIadjusted models) and 2hGlu 2 (GIPR), as well as confirming the recently iden tified signals for fasting glucose [17] [18] [19] at FOXA2, PPP1R3B, PCSK1 and PDX1. FOXA2 is a forkhead transcription factor that regulates PDX1 expression, and PDX1 encodes a transcription factor critical for pancreatic development 20 . PDX1 mutations have been linked to maturityonset diabetes of the young 4 (MODY4) 21 , pancreatic agen esis 22 and permanent neonatal diabetes 23 , although we observed no significant association with T2D in DIAbetes Genetics Replication and Metaanalysis (DIAGRAM) Metabochip analyses 24 (Fig. 1) .
Given the overlap between genetic loci for fasting glucose and other metabolic traits, we performed a systematic search of all glycemic loci and their associations with other metabolic traits using data available through other consortia [25] [26] [27] . In DIAGRAM Metabochip analyses 24 , 22 (>60%) of the now 36 loci associated with fasting glucose at genome wide significance showed association (P < 0.05; false discovery rate (FDR) q < 0.05) with T2D ( Fig. 1) . In all cases, the glucoseraising allele was associated with increased risk of T2D, yet fasting glucose effect sizes and T2D ORs were weakly correlated ( Fig. 2a) .
Genebased analyses confirmed many of the loci identified in singleSNP analyses ( Supplementary Table 3a ) and identified another 9 genomic regions (containing 14 genes) with significant association signals (P < 5 × 10 −6 ), including some with biological candidacy, such as the HKDC1 gene that encodes a putative hexokinase 28 .
Fasting insulin concentration
In 108,557 individuals, we identified 17 additional loci with genome wide significant associations to fasting insulin concentration and confirmed known associations 1 . These newly identified loci include variants in or near HIP1, TET2, YSK4, PEPD and FAM13A ( Figs. 3 and 4) , as well as SNPs near loci previously associated with other metabolic traits, including T2D 6 (TCF7L2 and PPARG), BMI 29 (FTO), waisthip ratio (WHR) 26 (LYPLAL1, RSPO3 and GRB14), triglycerides 27 (ANKRD55MAP3K1) and adiponectin 30 (ARL15). We also confirmed the recent asso ciations with fasting insulin at GRB14, PPP1R3B, LYPLAL1, IRS1, UHRF1BP1 and PDGFC 19 . The ANKRD55MAP3K1 association is of interest, as the MAP3K1 protein regulates expression of IRS1 (ref. 31) as well as activation of nuclear factor (NF)κB 32, 33 and the cJun Nterminal kinase (JNK) pathway 34 , both of which are centrally impli cated in insulin resistance 35, 36 . Furthermore, data from DIAGRAM Metabochip analyses show that the insulinraising allele at this SNP is strongly associated with increased risk of T2D 24 .
In contrast to fasting glucose ( Supplementary Fig. 5a ), in fasting insulin analyses adjusted for BMI, we observed a systematic decrease in the standard errors of the SNP effect estimates ( Supplementary  Fig. 5b ), perhaps because BMI explains more of the variance in fasting insulin levels (R 2 = 32.6%) than in fasting glucose levels (R 2 = 8.6%) or 2hGlu (R 2 = 11.0%) (data from the Fenland study). Therefore, BMI adjustment removes more variance in fasting insulin, thereby rendering genetic associations more readily detectable. This idea is supported by the identification of another five loci in BMI adjusted models by this approach ( Table 1 and Supplementary Figs. 3 and 4). As expected, BMI adjustment abolished fasting insulin associations at FTO (P = 0.71; Supplementary Table 2b ), suggesting that the association with fasting insulin is mediated entirely through association with BMI.
In total, 13 of the 19 loci associated with fasting insulin concentration also showed associations with T2D (P < 0.05; FDR q < 0.05) ( Fig. 1) , with the insulinraising allele associated with higher risk of T2D, except at TCF7L2 (Fig. 2b,c) , where the allele associated with lower fasting insulin was associated with higher fasting glucose levels ( Table 1) . Notably, the loci associated with fasting insulin showed a pattern of association with lipid traits consistent with insulin resistance, which is not observed for either fasting glucose or 2hGlu loci ( Fig. 1) . Thirteen (~68%) of the 19 loci were associated with highdensity lipoprotein (HDL)cholesterol (q < 0.05): all insulinraising alleles were associ ated with lower HDL levels, and nine of these were also associated with higher triglycerides (q < 0.05) ( Fig. 1) . Further, the insulin raising alleles of four SNPs were associated with higher WHR (adjusted for BMI) (q < 0.05) ( Fig. 1) , another trait linked to insulin resistance, and five SNPs were also associated with BMI, although with inconsistent direction (q < 0.05) ( Fig. 1) .
In genebased analyses, we focused on BMIadjusted results to account for the variance in fasting insulin explained by BMI. Beyond those loci containing genomewide significant SNPs, we identified 7 distinct regions (containing 22 genes) after Bonferroni correction (P < 5 × 10 −6 ). Among these genes, we identified many for which pre vious biological evidence suggests their role in pathways involved in insulin secretion or action ( Supplementary Table 3b ). Although the npg A r t i c l e s association for the lead SNP in PPARD did not reach genomewide significance (P = 3.9 × 10 −6 ), the PPARD gene-a regulator of adipose, hepatic and skeletal muscle metabolism 37 -reached the genebased sig nificance threshold (P < 1 × 10 −6 ). PPARD agonists have also been shown to induce insulinsensitizing effects in a mouse model 38 . In addition, we identified PTEN to be associated ( Supplementary Table 3b ), a gene previously suggested to affect glucose metabolism through regulation of insulin signaling 39 , and in which a musclespecific dele tion protected mice from insulin resistance and diabetes resulting from highfat feeding 40 . WARS (tryptophanyl-tRNA synthetase) catalyzes the aminoacylation of tRNA(Trp) with tryptophan. The intronic SNP rs3783347 is associated with WARS expression in liver: the glucose-raising allele associated with lower mRNA expression (age-and sex-adjusted P = 4.19 × 10 −5 ) and is in perfect LD (r 2 = 1, D = 1) with a 3′ UTR SNP in SLC25A47 (rs3736952) and in modest LD (r 2 = 0.3, D = 1) with a nonsynonymous p.Arg135Leu alteration (qualified as tolerated by SIFT and probably damaging by Polyphen). Nearby, YY1 (YY1 transcription factor) codes for a zinc-finger transcription factor involved in regulating a broad set of promoters. It has been suggested that YY1-regulated transcription is linked to glucose metabolism via O-GlcNAcylation 58 .
KL (klotho) encodes a type I membrane protein related to β-glucosidases. rs576674 lies ~36 kb upstream of KL. Variation in KL has been associated with insulin regulation, insulin resistance phenotypes and cardiovascular disease in some studies 14, 15, 59, 60 , but KL variants were not associated with diabetes risk 61 . The various SNPs in these studies are all in weak LD with rs576674 (r 2 < 0.125). Variation in KL is also associated with bone metabolism and may have a role in associations of energy metabolism with bone metabolism 62, 63 .
TOP1 (topoisomerase (DNA) I). rs6072275 is intronic in TOP1 and lies in a large region of high LD in Europeans, which includes the plausible biological candidate LPIN3 (lipin 3). In mice, a related homolog, Lpin1, is associated with fatty liver dystrophy 64 , a phenotype similar to human lipodystrophy (loss of body fat, fatty liver, hypertriglyceridemia and insulin resistance). Lpin1 mRNA is expressed at high levels in adipose tissue and is induced during differentiation of preadipocytes, suggesting that lipin is required for normal adipose tissue development, whereas LPIN2 has been suggested to be associated with T2D and glucose metabolism 65 .
rs6072275 lies in the middle of a large copy-number variation (CNV) that extends from within the 3′ end of TOP1 to the 5′ end of PLCG1 (phospholipase C, γ1). DNLZ contains rs3829109, which is in low LD with a well-established locus for inflammatory bowel disease. Two recent publications reported that the CARD9 SNP rs10781499 (r 2 = 0.29) is associated with ulcerative colitis 66 , and CARD9-SNAPC4 SNP rs4077515 (r 2 = 0.27) is associated with Crohn's disease and ulcerative colitis 67, 68 . Several genes are located in the region, but few with high plausibility for a role in glycemia.
AMT encodes the mitochondrial aminomethyltransferase, which is a critical component of the glycine cleavage system. Depending on the AMT transcript, rs11715915 is located in the 3′ UTR or within coding regions, where it causes a synonymous substitution. This SNP is also located downstream of TCTA (T-cell leukemia translocation altered), which has no known metabolic function, and upstream of RHOA (ras homolog family member A). RHOA is a signaling molecule involved in actin cytoskeleton stability and reorganization 69 that binds and activates Rho kinase (ROCK), a regulator of insulin transcription 70 and action 71 that is differentially regulated in T2D 72 and is hypothesized to have a role in glucose homeostasis 71 .
GLS2 encodes liver-expressed glutaminase 2, which is required for hydrolysis of glutamine. rs2657879 causes a benign (according to Polyphen) amino-acid change (p.Leu581Pro) in the GLS2 protein. The GLS2 protein is highly expressed (Human Protein Atlas) by both liver and pancreas, and it has been shown in liver tumors that alterations in the balance of the activity of GLS2:GLS1 (the kidney-specific homolog) is important for regulating glutamate metabolism 73 . The other gene in this region, SPRYD4 (SPRY domain containing 4), has no known function in metabolism.
RREB1 (ras responsive element-binding protein 1) encodes a zinc-finger transcription factor, with rs17762454 lying in an intron in the gene. The protein product of RREB1 binds to RAS-responsive elements (RREs) of gene promoters, including the CALCA (encoding calcitonin) gene promoter. The role of RREB1 in energy metabolism is not known. An uncorrelated SNP at this locus (rs675209) was associated with serum urate levels (P = 1.0 × 10 −9 ) in a GWAS of serum urate, gout and cardiovascular disease risk factors 74 . Another gene at this locus, SSR1 (signal sequence receptor, α), encodes a glycosylated endoplasmic reticulum (ER) membrane receptor associated with protein translocation across the ER membrane. Reactome pathway analysis places this gene in a module with key roles in the synthesis and function of insulin, insulin-like growth factors and ghrelin, making this gene a plausible biological candidate at this locus (REACTOME: REACT_15380). A third gene at this locus, CAGE1, encodes cancer antigen 1. CAGE1 has no known role in metabolism.
Fasting insulin
TET2 encodes the tet oncogene family member 2, isoform b, which catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. The enzyme is involved in myelopoiesis, and defects in this gene have been associated with several myeloproliferative disorders (NCBI RefSeq). Perhaps more relevant to glycemic regulation is PPA2, which encodes the inorganic pyrophosphatase 2 isoform 1 precursor. Its protein product is localized to mitochondria; it has high homology to members of the inorganic pyrophosphatase family, including the signature sequence that is essential for its catalytic activity (NCBI RefSeq). Pyrophosphatases catalyze the hydrolysis of pyrophosphate to inorganic phosphate.
HIP1 encodes the huntingtin-interacting protein 1, a membrane-associated protein that colocalizes with huntingtin. It is ubiquitously expressed, with the highest level found in brain. Loss of normal huntingtin-HIP1 interaction in Huntington's disease may contribute to a defect in membrane-cytoskeletal integrity in the brain. Of interest to insulin action, HIP1 is involved in clathrin-mediated endocytosis and trafficking. Mice transgenic for the mutated form of huntingtin develop diabetes 75, 76 ; however, although mice with double knockout of Hip1 and Hip1r have severe vertebral defects, suffer from dwarfism and die in early adulthood, they do not show any fasting glucose abnormalities 77 . The lead SNP (rs1167800) is only 104 bp away from a missense SNP (rs1167801), encoding a glutamic acid-to-histadine amino-acid change; however, LD between the SNPs is low (r 2 = 0.196).
FAM13A (family with sequence similarity 13, member A) encodes a protein with unknown function. Previous GWAS for lung function measures 78 and chronic obstructive pulmonary disease 79 described variants in FAM13A that affect these traits. SPP1, encoding osteopontin, a secreted matrix glycoprotein and proinflammatory cytokine involved in cell-mediated immunity, is within 1 Mb. Mice exposed to a high-fat diet show increased circulating osteopontin, and (continued) npg A r t i c l e s overexpression of Spp1 in the macrophages recruited into adipose tissue improved insulin sensitivity 80 , and SPP1 was highly expressed in obese twins relative to their nonobese siblings 81 . Recent work linked osteopontin to β-cell function through the gastric inhibitory pathway (GIP) pathway 82 . In carriers of the GIPR variant associated with impaired glucose and GIP-stimulated insulin secretion, osteopontin levels were lower compared to noncarriers. In addition, both GIP and osteopontin prevented cytokine-induced apoptosis and osteopontin-stimulated cell proliferation of functional β-cell mass.
PEPD (peptidase D) encodes a member of the peptidase family. The protein forms a homodimer that hydrolyzes dipeptides or tripeptides with a C-terminal proline or hydroxyproline residue. The enzyme serves an important role in the recycling of proline and may be rate limiting for collagen production. CEBPA (CCAAT/enhancer binding protein (C/EBP) α) is ~100 kb downstream of the lead SNP and encodes a transcription factor expressed in adipose tissue that regulates a number of genes involved in lipid and glucose metabolism. A SNP in low LD with our lead SNP was previously associated with triglyceride levels 83 . Cells from Cebpa −/− mice show a complete absence of insulin-stimulated glucose transport, secondary to reduced gene expression and tyrosine phosphorylation of the insulin receptor and IRS1 (ref. 84) . CEBPA also modulates expression of leptin by binding to the promoter of the gene 85 , and our lead SNP showed modest association with BMI in previous GIANT meta-analyses (P = 0.005).
YSK4 (Sps1/Ste20-related kinase homolog) contains rs1530559 in an intron. This gene has no known function in human energy metabolism. Three other genes at this locus also have no known role in energy metabolism, including RAB3GAP1 (RAB3 GTPase-activating protein subunit 1 (catalytic), encoding the catalytic subunit of a Rab GTPase-activating protein and mutated in Warburg micro syndrome; CCNT2 (cyclin T2), belonging to the highly conserved cyclin family, whose members are characterized by marked periodicity in protein abundance through the cell cycle; and ACMSD (aminocarboxymuconate semialdehyde decarboxylase), involved in the de novo synthesis pathway of nicotinamide adenine dinucleotide (NAD) from tryptophan. ACMSD has been implicated in the pathogenesis of several neurodegenerative disorders.
2-hour glucose
ERAP2 (endoplasmic reticulum aminopeptidase 2) encodes an aminopeptidase that hydrolyzes N-terminal amino acids of protein or peptide substrates. The lead SNP is strongly associated with ERAP2 expression in liver (P = 1.1 × 10 −55 ) and in lymphoblastoid cell lines in individuals from the CEU (P = 8 × 10 −21 ) and Yoruba from Ibadan, Nigeria (YRI) samples (P = 2 × 10 −15 ). Also near to this lead SNP is LNPEP (leucyl/cystinyl aminopeptidase), which is widely expressed and well characterized in muscle and fat cells. In response to insulin, LNPEP translocates to the cell surface and colocalizes with GLUT4 (ref. 86) . Although the role it has in insulin action is unknown, this translocation is impaired in individuals with T2D 86 . PCSK1 is also within 500 kb of the lead SNP, although it is on the other side of a recombination hotspot (supplementary Fig. 4d ).
Box 1 continued
2-h glucose
In 42,854 individuals, we identified 4 additional loci that were associ ated with 2hGlu ( Table 1 and Supplementary Figs. 3 and 4) , includ ing a signal near ERAP2 and 3 signals near loci previously associated with fasting glucose 1 (GCK), HDLcholesterol 27 (PPP1R3B) and T2D 6 (IGF2BP2), as well as confirming the 5 previous associations 2 . To determine whether these associations reflected differences in the response to a glucose challenge or were partly driven by effects on fast ing glucose, we also performed analyses adjusted for fasting glucose.
No additional loci were found to associate with genomewide signifi cance after adjustment for fasting glucose concentration, although the association of GCK with 2hGlu was severely attenuated (β = 0.04 (s.e.m. = 0.016) mM per allele; P = 0.005 versus β = 0.1 (0.016) mM per allele; P = 5.3 × 10 −11 in the model unadjusted for fasting glucose), suggesting that the association with 2hGlu is driven, at least in part, by a primary association with fasting glucose (Supplementary Table 2d) .
The association of SNPs near GCK with both fasting glucose and 2hGlu suggests a generalized increase in the glucose setpoint, con sistent with inactivating mutations in GCK that cause MODY 41 . As for fasting glucose, when 2hGlu models were adjusted for BMI, no systematic differences were observed, although, again, the rs7651090 SNP in IGF2BP2 reached genomewide significance ( Table 1) .
Eight of the nine SNPs associated with 2hGlu at genomewide levels of significance were also associated with T2D (q < 0.05) ( Fig. 1) , although the 2hGluraising alleles at PPP1R3B, GCKR and VPS13C C2CD4AC2CD4B were associated with lower risk of T2D (Fig. 2d) , consistent with their association with lower fasting glucose levels ( Table 1 and Supplementary Table 2e ).
In addition to SNPs with associations that reached genomewide significance in singleSNP analyses, we identified three regions (con taining six genes) showing association with 2hGlu in genebased analyses. These included the HKDC1 gene, as well as an association signal at CRHR1 (P = 2 × 10 −6 ) ( Supplementary Table 3c ), mostly driven by the lead SNP in this gene (rs17762954), which approached genomewide significance (P = 7.4 × 10 −7 ). CRHR1, together with GIPR, belongs to the family of class B G protein-coupled recep tors (GPCRs) and is highly expressed in pancreatic βcells, where stimulation of the receptor potentiates insulin secretion in response to glucose 42 .
Fine mapping of established loci
Analyses at higher SNP density around previously established loci did not generally yield stronger associations or more plausible functional variants ( Supplementary Table 4 ). For fasting glucose concentration, markedly more significant SNPs or larger effect sizes than the previous lead SNP were observed for 4 of the 16 loci: PROX1, GCK, ADRA2A and VPS13CC2CD4AC2CD4B (Supplementary Table 4 ). Regional plots for these loci are shown in Supplementary Figure 6 . Although the association for the new lead SNP near ADRA2A was not mark edly more significant than the previous lead SNP, the effect size was almost double that of the previous lead SNP ( Supplementary Table 4 ). However, this and other new lead SNPs lacked more plausible func tionality. The new lead SNP at VPS13CC2CD4AC2CD4B, previously associated with proinsulin 43 , is far more significant and of larger effect size than the previous lead SNP (β = 0.0273 (s.e.m. = 0.0035) mM per allele; P = 4.8 × 10 −15 versus β = 0.0057 (0.0036) mM per allele; P = 0.111; r 2 = 0.27). For fasting insulin concentration, another SNP downstream of IGF1 was found to be more significant and had a larger effect size, although with no known functionality ( Supplementary  Fig. 6 and Supplementary Table 4 ). For 2hGlu, another SNP at VPS13CC2CD4A-C2CD4B was again more significant than the previ ous lead SNP ( Supplementary Fig. 6 and Supplementary Table 4 ) and was previously associated with diabetes in Chinese individuals 44 .
Pathway analysis
Next, we explored whether glycemic loci were enriched for connec tivity between genes representing particular pathways or processes. To do this, we used GRAIL software 45 and investigated both an npg A r t i c l e s excess of connectivity between the established loci (that reached genomewide significance) and then between established loci and those loci that did not reach genomewide significance but showed a lower level of significance for association (P < 0.0005) (Online Methods). We aimed to establish whether there were any biologically relevant genes among this longer list of suggestively associated loci. This less stringent threshold yielded 218, 155 and 100 regions for fast ing glucose, fasting insulin and 2hGlu, respectively. To further assess whether the established loci represented common biological path ways, we used MAGENTA to undertake gene set-enrichment analyses (Online Methods).
We found that genes near the 36 loci associated with fasting glucose concentration had a high degree of connectivity (see Online Methods for definition of how genes were selected). Eight genes showed highly significant similarity to genes in other associated loci at P GRAIL < 0.01 and were connected by keywords such as 'glucose' , 'insulin' , 'pancreatic' and 'diabetes' (Supplementary Fig. 7 and Supplementary Table 5a) , at levels greater than those expected by chance (P permutation = 0.003). We observed less connectivity among the loci that were associated with fasting insulin and 2hGlu at genomewide significance, with no genes reaching P GRAIL < 0.01 for fasting insulin ( Supplementary Table 5b ) and only one out of nine genes reaching this threshold for 2hGlu (P permutation = 0.07) ( Supplementary Table 5c ).
Among the list of 218 suggestively associated loci for fasting glucose (P < 0.0005), we observed that 13 genes were connected to the genome wide significant loci at P GRAIL < 0.01, more than expected by chance (P permutation = 0.003) (Supplementary Table 6a) . These included genes such as GLP1R (P GRAIL = 3.3 × 10 −7 ; a glucagon receptor that mediates the GLP1 incretin effect and stimulates insulin release), IRS2 (P GRAIL = 6.9 × 10 −5 ; central to development and maintenance of βcell mass and function 46, 47 ) and INS (P GRAIL = 2.5 × 10 −6 ; the insulin gene encoding proinsulin). The presence of these genes and other biologi cally plausible genes support our conjecture that many of the SNPs approaching genome wide significance are likely to represent true associations. Of the 155 suggestively associ ated loci for fasting insulin (adjusted for BMI), we observed that 7 were connected to the genomewide significant loci at P GRAIL < 0.01, more than expected by chance (P permutation = 0.002), and these genes included INSR (P GRAIL = 1.5 × 10 −4 ; encoding insulin receptor precur sor), CD36 (P GRAIL = 0.001; previously impli cated in insulin resistance 48 ), GCG (P GRAIL = 0.008; glucagon gene) and HNF1A (P GRAIL = 0.005; mutations in the gene are associated with MODY3 (ref. 49)) ( Supplementary  Table 6b ). Of the 100 suggestively associated loci for 2hGlu (P < 0.0005), we found that 3 reached P GRAIL < 0.01 (P permutation = 0.014), and the gene highlighted as most biologically connected to the genomewide significant loci was again HNF1A (P GRAIL = 3.4 × 10 −4 ) ( Supplementary Table 6c ).
Using MAGENTA, we identified four path ways enriched for fasting glucose associations: GOTERM pathways lens development in cam eratype eye (P = 0.004), PANTHER processes gut mesoderm development (P = 0.009), other steroid metabolism (P = 0.02) and KEGG MODY pathway (P = 0.03), although these were no longer significant (P > 0.05) after removing lead genes, all of which were known fasting glucose loci (PROX1 for eye and gut and G6PC2 and GCK for steroid and MODY pathways, respectively).
Directional consistency between discovery and follow-up
Given the wealth of biologically plausible genes in loci with associations that almost reached genomewide significance ( Supplementary Table 6a -c) and the deviation of the observed distribution from the expected in quantilequantile plots, even after removing all established loci (Supplementary Fig. 8a-d) , we hypothesized that additional loci not reaching genomewide signi ficance were likely to represent true associations with small effects. To establish the presence of further true associations that did not reach genomewide significance, we compared SNP associations in discovery studies (those included in the original metaanalyses for 42,078 (fasting glucose), 34,230 (fasting insulin) and 15,252 (2hGlu) individuals) 1,2 with those in the followup studies (consisting of 85,710 (fasting glucose), 69,240 (fasting insulin) and 27,602 (2hGlu) individuals). We identified all SNPs that had a nominally significant association (P < 0.05) in the followup studies alone and, for these SNPs, performed a binomial test to determine whether more SNPs than expected by chance (50%) had a consistent direction of effect with that observed in the discovery analyses. We were also able to make comparisons among SNPs that were nominated for followup analysis by different consortia (Supplementary Fig. 9a-d) .
For 
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Association with lower levels of trait Other traits Figure 1 Associations between glycemic loci and T2D, HDL-cholesterol (HDL-C) and triglyceride concentrations, BMI and WHR. Loci associated with these traits (P < 0.05) are highlighted. Those with positively correlated effect directions are shown in yellow, and those with negative correlations are shown in blue. Those which did not reach q < 0.05 in FDR analyses are indicated by a diagonal line through the corresponding rectangle. FG, fasting glucose; FI, fasting insulin. npg associations (P < 0.05) compared to that expected by chance (fast ing glucose, P binomial = 5.01 × 10 −12 ; fasting insulin, P binomial = 7.58 × 10 −13 ; fasting insulin (adjusted for BMI), P binomial = 9.76 × 10 −9 ; 2hGlu, P binomial = 2.37 × 10 −6 ; Supplementary Fig. 9a-d and Supplementary Table 7 ). FDR analyses suggested that a number of these nominal associations in the followup studies are true posi tives for fasting glucose and fasting insulin in particular (fasting glu cose, 23%; fasting insulin, 24%; Supplementary Table 7) . Notably, when we evaluated consistency of association with fasting insulin (between discovery and followup stages) among SNPs submitted to the Metabochip by other consortia, SNPs submitted by the Genetic Investigation of ANthropometric Traits (GIANT) Consortium (anthropometric traits) (P binomial = 1.52 × 10 −8 ) and the Global Lipids Genetics Consortium (GLGC) (lipid traits) (P binomial = 1.15 × 10 −6 ) and for BMI and triglycerides in particular also showed a marked excess of directional consistency (Supplementary Fig. 9b and Supplementary Table 7 ). When we performed the same test for fasting insulin concentration adjusted for BMI, the observed enrichment among SNPs submitted by GIANT and GLGC was attenuated ( Supplementary Fig. 9c and Supplementary Table 7) , although SNPs nominated to follow up on triglyceride associations remained the most significant (P = 3.18 × 10 −7 ; Supplementary  Fig. 9c and Supplementary Table 7) . Of the 3,353 SNPs submitted for followup study of triglyceride associations, 158 SNPs showed nominal significance (P < 0.05) in followup studies and consistent direction of association with fasting insulin (adjusted for BMI) in both discovery and followup stages ( Supplementary Table 7 ). In 139 (88%) of these SNPs, the insulin raising alleles were associated with higher levels of triglycerides, consistent with the positive correlations between fasting insulin and triglyceride associations observed among the genomewide significant loci for fasting insulin concentration (Fig. 1) .
DISCUSSION
In the current metaanalysis of ~66,000 Metabochip followup SNPs in up to 133,010 individuals, we identified a large number of loci that associated with glycemic traits, explaining 4.8%, 1.2% and 1.7% of the vari ance in fasting glucose, fasting insulin and 2hGlu, respectively. Of the 53 glycemic loci, 33 are also associated with increased T2D risk (q < 0.05), extending the overlap between glycemic and T2D loci. Given the current DIAGRAM effective sample size of 106,953 individuals, we can exclude an effect on T2D of 1.04 with 80% power to detect alleles more frequent than 5%, effectively confirming that the overlap is incomplete and that many loci associated with glycemic traits have no dis cernible effect on T2D ( Figs. 1 and 2) .
Previously, we had detected only two loci associated with fasting insulin concentration and had hypothesized that this might be due to a different genetic architecture for this trait compared to fasting glucose, with potentially smaller effect sizes, lower frequency alleles or greater environmental influence on fasting insulin 1 . In the current metaanalysis including up to 108,557 indi viduals (compared to 62,264 individuals previously), we expanded the number of loci associated with this trait to 19. Of note was the effect of BMI adjustment on our ability to detect additional loci (five nono verlapping with unadjusted results) 19 . We also noted that some of the loci influencing fasting insulin that were uncovered after BMI adjust ment are likely to have been negatively confounded in previous efforts: at some loci, the insulinraising allele was nominally associated with lower BMI (potentially via insulin resistance, attenuating the anabolic effects of insulin). Given the positive correlation between BMI and fast ing insulin, it is likely that this association previously masked their effect on fasting insulin. Fasting insulin loci showed directionally consistent association with lipid levels (HDL and triglycerides); that is, the insu linraising allele was associated with lower HDL and higher triglyceride levels, a hallmark combination in insulinresistant individuals. We also observed some overlap between fasting insulin loci and those associated with abdominal obesity (Fig. 1) . Jointly, these data suggest links of these fasting insulin loci to insulin resistance-related phenotypes. Indeed, some of the fasting insulin loci identified, such as IRS1 and PPARG, are classically known to exert effects on insulin action or sensitivity 50, 51 .
There are now 36 established fasting glucose loci, many of which contain compelling biological candidate genes with plausible causal ity, including those encoding transcription factors with known roles in pancreas development (for example, PDX1, FOXA2, PROX1 and GLIS3) and genes involved in βcell function and insulin secretion npg A r t i c l e s pathways (SLC2A2, GCK and PCSK1). For 2hGlu, only nine associated loci have been established to date, which likely reflects the smaller sample size available and the consequent reduction in power.
Comparing the consistency of the direction of associations for gly cemic traits between discovery and followup studies suggests that we are observing more directionally consistent associations than expected by chance among Metabochip followup SNPs ( Supplementary  Fig. 9a-d) . This finding, combined with the excess of biologically plausible genes among the loci on the edge of being significant (Supplementary Table 6a-c) , suggests that, beyond the genome wide significant loci, there is a more extensive list of loci still likely to contain true associations. Indeed, some of these loci are implicated by genebased analyses, which identify genes with compelling biologi cal credentials. For fasting insulin, these analyses revealed additional loci with previously suggested links to insulin resistance (PPARD and PTEN). These results lend further support to the proposal that a long tail of common variants of small effect size is likely to account for a substantial proportion of the variance of complex traits 7, 8 .
Of note is the number of glycemic loci associated with other meta bolic traits (q < 0.05; 34 of 53) and also at genomewide levels of significance (P < 5 × 10 −8 ; 14 of 53) ( Fig. 1) , potentially implicating pleiotropic effects. Further support for this notion comes from the analysis of loci nominated for the Metabochip by other consortia and their associations with glycemic traits (Supplementary Fig.  9a-d) . Indeed, some of the loci associated with glycemic traits at genomewide significance levels were not originally nominated for the Metabochip for followup study by MAGIC ( Table 1) . Metabochip data available across all contributing consortia will facilitate systematic exploration of these correlated phenotypes with more sophisticated statistical methods for joint analysis [52] [53] [54] , yielding greater insight into the underlying pathways and genetic networks they represent. As data from human genetic networks accrue, we will be better placed to test whether there is support for the notion of 'hub' genes-that is, genes highly connected with others in the network, proposed by experi ments in Caenorhabditis elegans to act as buffers for genetic variation, that could act as modifier genes for many different disorders 55 .
In summary, we present a large number of genomewide significant loci influencing glycemic traits, many with a compelling biological basis for their association, as well as a number of loci not previously implicated in glycemic regulation, for which fine mapping and func tional followup study will expand and improve understanding. Use of the Metabochip for deep follow up has identified additional loci involved in glycemic regulation that, due to insufficient sample size and power, did not reach genomewide significance. Consideration of such loci in future studies will better exploit data from GWAS and complimentary approaches and further improve our biological under standing of glycemic control and the etiology of diabetes. 
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Study design. The Illumina CardioMetabochip (Metabochip) is a custom Illumina iSELECT array of 196,725 SNPs. It has been designed to support efficient largescale followup analysis of putative associations for glycemic (including fasting glucose, fasting insulin and postchallenge glucose (2hGlu) concentrations and other metabolic and cardiovascular traits ( Supplementary  Fig. 1) 9 and to enable the fine mapping of established loci. Overall, there were 65,435 SNPs genotyped on the Metabochip for follow up of previous associations, including a total of 23 cardiometabolic traits. Traits contribut ing SNPs to the Metabochip were prioritized into primary (including fasting glucose) and secondary (including fasting insulin and 2hGlu), contributing ~5,000 and ~1,000 SNPs, respectively, from the most significantly associ ated variants for each phenotype in the discovery metaanalyses from each contributing consortium. This included 5,055 SNPs for follow up of fasting glucose, 1,046 for fasting insulin and 1,038 for 2hGlu associations. In the present analysis, we focused our analysis on this set of followup SNPs avail able on the Metabochip to establish variants among these SNP associated with glycemic traits. Although we also included newly available studies genotyped on genomewide platforms, we limited our primary analyses to only these ~66,000 SNPs.
Studies.
In the present effort, collaborating studies within the MetaAnalysis of Glucose and Insulin related traits Consortium (MAGIC) provided results for the 66,000 followup SNPs genotyped on Metabochip on a maximum total of 133,010 (fasting glucose), 108,557 (fasting insulin) and 42,854 (2hGlu) indi viduals. In addition to those newly genotyped on the Metabochip platform, in our overall metaanalysis, we were able to include further studies that had genotyped or imputed the same SNPs on other platforms. The largest propor tion of our entire sample was directly genotyped on the Metabochip and com prised 53,622 (fasting glucose), 42,384 (fasting insulin) and 27,602 (2hGlu) individuals from 26, 21 and 12 studies, respectively. We were also able to recruit 11,690 (fasting glucose) and 8,813 (fasting insulin) individuals from up to 4 additional GWAS (Prevend, Ascot (fasting glucose only), Prosper and TRAILS) ( Supplementary Table 1 ) not included in the original metaanalysis 1 . From another MAGIC study of sexspecific associations with glycemic traits (I.P. on behalf of the MAGIC authors, personal communication), we were able to recruit another 15 and 13 independent studies comprising up to 25,618 and 23,130 individuals for fasting glucose and fasting insulin, respectively. The above studies were combined in a single fixedeffects metaanalysis with those studies included in the original GWAS 1,2 , including 20 (fasting glucose), 19 (fasting insulin) and 9 (2hGlu) studies and 42,080 (fasting glucose), 34,230 (fasting insulin) and 15,252 (2hGlu) individuals, as described previously 1, 2 . The study and individual counts from the original GWAS excluded the fam ilybased SardiNIA study, where, initially, a large number of the individuals had imputed genotype data only. The entire sample was directly genotyped on Metabochip, and the resulting data were included in place of the original GWAS data. Some studies had genotyping data available from both Metabochip and genomewide arrays but from entirely independent samples within the study (Supplementary Table 1) . Full study characteristics of all Metabochip stud ies are shown in Supplementary Table 1 , and data from discovery genome wide studies, and those from the sexspecific analyses are reported elsewhere (refs. 1,2 and I.P. on behalf of the MAGIC authors, personal communication). All participants of the main analysis were of European descent and were mostly adults, although data from a total of 7,872 and 7,164 adolescents were also included in the fasting glucose and fasting insulin metaanalyses, respectively (NFBC86, Leipzigchildhood_IFB, TRAILS and ALSPAC studies). All stud ies were approved by local research ethic committees, and all participants gave informed consent. Results from the CLHNS study of Filipino women (n = 1,682 and 1,635 for fasting glucose and fasting insulin, respectively) geno typed on Metabochip were also available and were included in supplementary analyses to compare effect directions with studies of individuals of European descent alone.
Phenotypes. Analyses were undertaken for fasting glucose and fasting insulin measured in mM and pM, respectively. 2hGlu was measured in mM. As in the previous MAGIC discovery analysis 1, 2 , individuals were excluded from the analysis if they had a physician diagnosis of diabetes, were on diabetes treatment (oral or insulin) or had a fasting plasma glucose concentration equal to or greater than 7 mM. Individual studies applied further sample exclu sions, including for pregnancy, nonfasting individuals and type 1 diabetes, as detailed in Supplementary Table 1 . Individuals from casecontrol studies ( Supplementary Table 1 ) were excluded if they had undergone hospitalization or blood transfusion in the 2-3 months before phenotyping took place. 2hGlu measures were carried out 2 h after a glucose challenge during an oral glucose tolerance test (OGTT). Measures of fasting glucose and 2hGlu made in whole blood were corrected to plasma level using the correction factor of 1. 13 (ref. 87) . Fasting insulin was measured in serum. Detailed descriptions of studyspecific glycemic measurements are given in Supplementary Table 1 .
Trait transformations and adjustment. Analyses were performed for untrans formed levels of fasting glucose, natural logarithm-transformed fasting insulin and untransformed 2hGlu using a linear regression model. All analyses were adjusted (if applicable) for age, study site and geographic covariates to evaluate the association using an additive genetic model at each genetic SNP variant.
BMI-adjusted analysis.
In the Fenland study (Supplementary Table 1) , we investigated the correlation between BMI and natural logarithm-transformed fasting insulin, fasting glucose and 2hGlu to establish the variation in each trait explained by BMI. Metaanalyses for each trait were also adjusted for BMI. Metabochip studies and new GWAS performed studylevel analyses adjusted for BMI. Most studies in the original GWAS (except deCode, GEMs, KORAF4 and TwinsUK) as well as from the studies analyzed in a sexspecific manner were included in BMIadjusted metaanalysis. The original discovery 2hGlu metaanalysis adjusted for BMI 2 was also included in these analyses. We also performed an analysis for 2hGlu adjusted for fasting glucose to investi gate whether additional variants would be identified with an effect on 2hGlu independent of fasting glucose and also to establish whether identified 2hGlu associations were driven by fasting glucose.
Genotyping and quality control. The Metabochip or other commercial genomewide arrays were used by individual studies for genotyping. Details are presented in Supplementary Table 1 or are reported elsewhere 1,2 . The quality control criteria for both Metabochip and genomewide arrays for fil tering of poorly genotyped individuals or lowquality SNPs before imputa tion included the occurrence of (i) a call rate of <0.95; (ii) sex discrepancies; (iii) ancestry outliers; (iv) heterozygosity ( Supplementary Table 1 ); (v) SNP minor allele frequency of <0.01; (vi) SNP HardyWeinberg equilibrium P < 1 × 10 −4 ; (vii) SNP effect estimate standard error (SE) ≥10; and (viii) SNP minor allele count (MAC) of <10 (calculated as the total number of observed alleles at each SNP multiplied by the MAF).
Studies with genomewide arrays undertook imputation using the HapMap CEU reference panel using MACH 88, 89 and IMPUTE 90,91 software ( Supplementary Table 1 ). Parameters used in imputation and filters applied to imputed genotypes are described in Supplementary Table 1 or were reported previously 1, 2 . From a total of ~2.5 million directly genotyped or imputed autosomal SNPs across the genome, studyspecific results for the ~66,000 Metabochip followup SNPs were considered for the present metaanalyses. SNPs at which there were metaanalysis results in more than 10,000 individuals were included in the analysis.
Statistical analysis.
Analyses of previous discovery studies are reported elsewhere 1, 2 , and those studies genotyped on the Metabochip are described in Supplementary Table 1 . SNP effect estimates and their standard errors (for an additive genetic model) were combined by inverse variance-weighted fixedeffects metaanalysis using METAL 92 and GWAMA 93 . Two parallel metaanalyses for each trait by different analysts were compared for consist ency. Individual cohort results were corrected for residual inflation of the test statistics using genomic control (λ) estimates. The genomic control values were estimated for each study, using either test statistics from all SNPs for the GWAS, whereas, for those studies genotyped on the Metabochip, genomic control λ estimates were derived from test statistics for 5,041 SNPs selected for followup analysis of QTinterval associations, as we perceived these to have the lowest likelihood of common architecture of associations with glyc emic traits. Individual study-level λ genomic control estimates are shown in npg
